SCHEMBL328280

SCHEMBL328280

CCc1nc(C(N)=O)c(Nc2ccc(C(=O)NC)cc2C)nc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDR P35968 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.37
PLAU P00749 1/20 0.36
PTK2 Q05397 2/20 0.36
MAPK14 Q16539 6/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TAS1R2 Q8TE23 1/20 0.36
EGFR P00533 1/20 0.35
PLK1 P53350 1/20 0.35
TOP2A P11388 1/20 0.34
MAPT P10636 1/20 0.34
SCN9A Q15858 1/20 0.34
LRRK2 Q5S007 1/20 0.34
EML4 Q9HC35 1/20 0.34
ALK Q9UM73 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10156687 0.92 MAPK14 (0.43) MAPK14
SCHEMBL10155938 0.89 PLAU (0.38) ALDH1A1HPGDRAB9ASMN1; SMN2KDR
SCHEMBL10126661 0.87 LRRK2 (0.48) PTK2MAPTLRRK2EML4ALK
SCHEMBL10157671 0.86 SCN9A (0.37) KDRIRAK4PLAUMAPK14EGFR
SCHEMBL17340264 0.85 PTK2 (0.35) ALDH1A1HPGDRAB9ASMN1; SMN2PLAU
SCHEMBL10126643 0.81 EML4 (0.43) EGFREML4ALK
SCHEMBL10128876 0.80 ALK (0.57) EML4ALK
SCHEMBL10156685 0.79 PTK2 (0.43) SMN1; SMN2PTK2EGFRMAPTSCN9A
SCHEMBL16305328 0.79 EML4 (0.41) SCN9AEML4ALK
SCHEMBL10157039 0.77 PTK2 (0.44) SMN1; SMN2PTK2TAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
EP-2428508-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2012-03-14 EP disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALDH1A1 1554/4885HPGD 4520/4885RAB9A 1850/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALDH1A1 1554/4885HPGD 4520/4885RAB9A 1850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.